
News|Videos|December 7, 2020
Closing Thoughts on Research into the Induction of Fetal Hemoglobin by FTX6058
Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on his closing thoughts on the research he conducted into the induction of fetal hemoglobin by FTX6058.
Advertisement
Pharmacy Times® interviewed Christopher Moxham, the senior vice president of discovery research at Fulcrum Therapeutics, on his presentation at the 62nd ASH Annual Meeting and Exposition. The presentation discusses research into the induction of fetal hemoglobin by FTX6058, a novel small molecule development candidate.
In this video, Moxham notes some closing thoughts on his research into the induction of fetal hemoglobin by FTX6058.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKD Outcome Set Elevates Patient-Reported Measures
2
FDA Expands Accelerated Approval of Sevabertinib to First-Line HER2-Mutant NSCLC
3
Tozorakimab Reduces COPD Exacerbations Across Eosinophil Levels in Phase 3 Trials
4
Community Pharmacy Can Win and Still Lose
5





































































































